Equity Profile

ZTS

Zoetis Inc.

Health CarePharmaceuticals$31.6B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures veterinary medicines and vaccines for livestock and pets....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, which is vital for long-term success.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ZTS Q2-2026 Earnings Preview

Context

Company Snapshot

Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures veterinary medicines and vaccines for livestock and pets. With a market cap of $32 billion, Zoetis plays a crucial role in the healthcare sector, focusing on improving the health and well-being of animals, which is increasingly important as global food production and pet ownership rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+4.50%

Avg Stock Reaction

-6.18%

Last Quarter Recap

In Q1-2026, Zoetis reported an EPS of $1.53, missing estimates by 5.09%. Following this disappointing result, the stock dropped by 21.50% the next day, highlighting investor concerns about the company's performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Zoetis' upcoming earnings report, especially after the recent miss. The market is looking for signs of recovery in profitability and growth.

Bull Case

If Zoetis can demonstrate strong revenue growth and improved margins, it could regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company fails to show improvement in key metrics or provides weak guidance, it could face further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the recent miss in Q1-2026, investors will be closely watching EPS to gauge whether the company can turn its performance around.

What guidance will management provide for revenue growth moving forward?

Guidance on revenue growth is critical for assessing the company's future prospects and will heavily influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zoetis' ability to rebound from its recent earnings miss, as the company has a strong track record of recovering from setbacks.

Supporting Evidence

Zoetis has consistently beaten EPS estimates in the past, with an 88% beat rate over the last eight quarters.

Options pricing suggests a lower expected move, which may indicate that traders are not fully pricing in a potential recovery.

The recent insider trading activity, although minimal, shows some level of confidence from insiders.

Key Risk

If the company can deliver an EPS above $1.60, it could significantly shift market sentiment in its favor.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Zoetis can recover from its recent earnings miss and provide a positive outlook for growth.

Bull Confirmed If

An EPS of $1.60 or higher would confirm a recovery in profitability and likely boost investor confidence.

Bear Confirmed If

An EPS below $1.50 would indicate ongoing challenges and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±3.68%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.68%, which is lower than the historical average realized move of 7.68%, suggesting that traders may be expecting a stable earnings report.

Options are pricing ±3.7% while ZTS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

77.9%

Calls (177K)P/C Ratio: 1.05Puts (644K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zoetis beats expectations and raises guidance, history suggests a potential stock increase of around 3.1% on the following day.

In-Line / Cautious

If results are in line with expectations but management remains cautious, the stock may experience a muted reaction.

Miss

If the company misses expectations again, history suggests a potential decline of about 21.50% on the next trading day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·1 sell

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management strategies and their impact on margins.
4Updates on international sales performance and growth opportunities.
5Any changes in guidance for the remainder of the fiscal year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures veterinary medicines and vaccines for livestock and pets....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, which is vital for long-term success.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ZTS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+4.50%

Avg Stock Reaction

-6.18%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Zoetis' upcoming earnings report, especially after the recent miss. The market is looking for signs of recovery in profitability and growth.

Bull Case

If Zoetis can demonstrate strong revenue growth and improved margins, it could regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company fails to show improvement in key metrics or provides weak guidance, it could face further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the recent miss in Q1-2026, investors will be closely watching EPS to gauge whether the company can turn its performance around.

What guidance will management provide for revenue growth moving forward?

Guidance on revenue growth is critical for assessing the company's future prospects and will heavily influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zoetis' ability to rebound from its recent earnings miss, as the company has a strong track record of recovering from setbacks.

Supporting Evidence

Zoetis has consistently beaten EPS estimates in the past, with an 88% beat rate over the last eight quarters.

Options pricing suggests a lower expected move, which may indicate that traders are not fully pricing in a potential recovery.

The recent insider trading activity, although minimal, shows some level of confidence from insiders.

Key Risk

If the company can deliver an EPS above $1.60, it could significantly shift market sentiment in its favor.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Zoetis can recover from its recent earnings miss and provide a positive outlook for growth.

Bull Confirmed If

An EPS of $1.60 or higher would confirm a recovery in profitability and likely boost investor confidence.

Bear Confirmed If

An EPS below $1.50 would indicate ongoing challenges and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±3.68%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.68%, which is lower than the historical average realized move of 7.68%, suggesting that traders may be expecting a stable earnings report.

Options are pricing ±3.7% while ZTS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

77.9%

Calls (177K)P/C Ratio: 1.05Puts (644K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zoetis beats expectations and raises guidance, history suggests a potential stock increase of around 3.1% on the following day.

In-Line / Cautious

If results are in line with expectations but management remains cautious, the stock may experience a muted reaction.

Miss

If the company misses expectations again, history suggests a potential decline of about 21.50% on the next trading day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·1 sell

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management strategies and their impact on margins.
4Updates on international sales performance and growth opportunities.
5Any changes in guidance for the remainder of the fiscal year.